Oral Dosage Form New Animal Drugs; Tiamulin
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The supplemental NADA provides for use of an increased strength of tiamulin concentrate solution in the drinking water of swine for the treatment of certain bacterial respiratory and enteric diseases.
Table of Contents Back to Top
- FOR FURTHER INFORMATION CONTACT:
- SUPPLEMENTARY INFORMATION:
- List of Subjects in 21 CFR Part 520
- PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
DATES: Back to Top
This rule is effective September 8, 2010.
FOR FURTHER INFORMATION CONTACT: Back to Top
Cindy L. Burnsteel, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8341, e-mail: firstname.lastname@example.org.
SUPPLEMENTARY INFORMATION: Back to Top
Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408, filed a supplement to NADA 140-916 for DENAGARD (tiamulin) Liquid Concentrate administered in drinking water for the treatment of certain bacterial respiratory and enteric diseases in swine. The supplemental NADA provides for use of a 12.5 percent tiamulin concentrate solution. The supplemental NADA is approved as of June 14, 2010, and 21 CFR 520.2455 is amended to reflect the approval.
Approval of this supplemental NADA did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.
The agency has determined under 21 CFR 25.33 that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:
PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS Back to Top
1.The authority citation for 21 CFR part 520 continues to read as follows:
2.In § 520.2455, revise paragraphs (a) and (b) to read as follows:
§ 520.2455 Tiamulin.
(a) Specifications. (1) Each gram of soluble powder contains 450 milligrams (mg) tiamulin hydrogen fumarate.
(2) Each milliliter (mL) of solution contains 125 mg (12.5 percent) tiamulin hydrogen fumarate.
(3) Each mL of solution contains 123 mg (12.3 percent) tiamulin hydrogen fumarate.
(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (d) of this section.
(1) No. 058198 for products described in paragraphs (a)(1) and (a)(2) of this section.
(2) No. 059130 for products described in paragraphs (a)(1) and (a)(3) of this section.
Dated: September 1, 2010.
Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.
[FR Doc. 2010-22277 Filed 9-7-10; 8:45 am]
BILLING CODE 4160-01-S